Segment Information (Tables)

9 Months Ended

Sep. 30, 2026

Schedule of segment reporting information, by segment

	Three Months Ended September 30,
	2026						2025
	Biopharm Division		Neurostimulation Division		Total		Biopharm Division		Neurostimulation Division		Total
Operating expenses:
Personnel and related expenses	$	2,927	$	445	$	3,372	$	2,521	$	296	$	2,817
Office space rental related expenses		1,001		29		1,030		1,003		54		1,057
Development expenses		1,191		-		1,191		1,083		-		1,083
Professional services and insurance		984		285		1,269		1,201		172		1,373
Depreciation		129		-		129		101		4		105
Other general and administrative expenses		439		102		541		180		110		290
Other (income) expense, net		(280)		(2)		(282)		(237)		42		(195)
Segment net loss	$	6,391	$	859	$	7,250	$	5,852	$	678	$	6,530

	Nine Months Ended September 30,
	2026						2025
	Biopharm Division		Neurostimulation Division		Total		Biopharm Division		Neurostimulation Division		Total
Operating expenses:
Personnel and related expenses	$	8,175	$	1,145	$	9,320	$	7,580	$	815	$	8,395
Office space rental related expenses		3,044		93		3,137		3,143		260		3,403
Development expenses		3,182		-		3,182		3,154		-		3,154
Professional services and insurance		3,202		626		3,828		4,018		638		4,656
Depreciation		387		-		387		299		8		307
Other general and administrative expenses		1,225		274		1,499		563		268		831
Other (income) expense, net		(614)		(339)		(953)		(894)		124		(770)
Segment net loss	$	18,601	$	1,799	$	20,400	$	17,863	$	2,113	$	19,976

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details